Skip to main content

Myokarditis nach Krebstherapie mit Immun-Checkpoint-Inhibitoren: Was zeigt die kardiale MRT?

Myocarditis after cancer treatment with immune checkpoint inhibitors: what does cardiac MRI show?

This is a preview of subscription content, access via your institution.


  1. 1.

    Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19:e447–e58

    CAS  Article  Google Scholar 

  2. 2.

    Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D et al (2020) Onkologische Kardiologie. Konsensuspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung, der Deutschen Gesellschaft für Pädiatrische Kardiologie und Angeborene Herzfehler und der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie. Kardiologe 14:267–293

    Article  Google Scholar 

  3. 3.

    Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636–2648 (48a–48d)

    Article  Google Scholar 

  4. 4.

    Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158–3176

    Article  Google Scholar 

  5. 5.

    Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F et al (2020) Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41:1733–1743

    CAS  Article  Google Scholar 

  6. 6.

    Friedrich MG (2020) Immune checkpoint inhibitor cardiotoxicity: what can we learn from real life data on CMR as a diagnostic tool? Eur Heart J 41:1744–1746

    Article  Google Scholar 

  7. 7.

    Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 22:1504–1524

    CAS  Article  Google Scholar 

  8. 8.

    Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140:80–91

    Article  Google Scholar 

  9. 9.

    Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Florian von Knobelsdorff.

Ethics declarations


F. von Knobelsdorff gibt an, dass kein Interessenkonflikt besteht.

Additional information


QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

von Knobelsdorff, F. Myokarditis nach Krebstherapie mit Immun-Checkpoint-Inhibitoren: Was zeigt die kardiale MRT?. Kardiologe 15, 423–426 (2021).

Download citation